Evidence map›Paper›PMID 37843370›Full record

ArticleJournal of virology2023

HIVepsilon-seq-scalable characterization of intact persistent proviral HIV reservoirs in women.

Kirston Barton, James M Ferguson, Ira W Deveson, Shane D Falcinelli, Katherine S James, Jennifer Kirchherr, Catalina Ramirez, Cynthia L Gay, Jillian M Hammond, Brent Bevear and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 4 countries.

Kirston BartonThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.ORCID 0000-0002-0410-4849
James M FergusonThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.
Ira W DevesonThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.
Shane D FalcinelliDepartment of Microbiology, University of North Carolina , Chapel Hill, North Carolina, USA.
Katherine S JamesUNC HIV Cure Center, University of North Carolina , Chapel Hill, North Carolina, USA.
Jennifer KirchherrUNC HIV Cure Center, University of North Carolina , Chapel Hill, North Carolina, USA.
Catalina RamirezDepartment of Medicine, University of North Carolina , Chapel Hill, North Carolina, USA.
Cynthia L GayDepartment of Medicine, University of North Carolina , Chapel Hill, North Carolina, USA.
Jillian M HammondThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.
Brent BevearThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.
Shaun L CarswellThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.
David M MargolisDepartment of Microbiology, University of North Carolina , Chapel Hill, North Carolina, USA.
Martin A SmithThe Garvan Institute of Medical Research , Sydney, New South Wales, Australia.
Adaora A AdimoraDepartment of Medicine, University of North Carolina , Chapel Hill, North Carolina, USA.
Nancie M ArchinUNC HIV Cure Center, University of North Carolina , Chapel Hill, North Carolina, USA.ORCID 0000-0002-7938-0389
University of North Carolina at Chapel Hill · USGarvan Institute of Medical Research · AUNew South Wales Department of Health · AU

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
UNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2M
The HIV Reservoir in Women: Implications for HIV cure interventionsR01AI134363 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARCHIN, NANCIE MARIE · 2017 to 2020
$2.2M
The Intersection of Sex, Innate Immunity and the HIV ReservoirR56AI170226 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARCHIN, NANCIE MARIE · 2022 to 2022
$592k
Reducing the HIV Reservoir: Next-Generation Latency Reversal Agents and T Cell Population TargetsF30AI145588 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALCINELLI, SHANE DAVID · 2019 to 2023
$217k
NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NIAID NIH HHS F30 AI145588NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI134363NIAID NIH HHS R56 AI170226NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI164567
6 · The paper itself

Abstract

importanceThe lack of a reliable method to accurately detect when replication-competent HIV has been cleared is a major challenge in developing a cure. This study introduces a new approach called the HIVepsilon-seq (HIVε-seq) assay, which uses long-read sequencing technology and bioinformatics to scrutinize the HIV genome at the nucleotide level, distinguishing between defective and intact HIV. This study included 30 participants on antiretroviral therapy, including 17 women, and was able to discriminate between defective and genetically intact viruses at the single DNA strand level. The HIVε-seq assay is an improvement over previous methods, as it requires minimal sample, less specialized lab equipment, and offers a shorter turnaround time. The HIVε-seq assay offers a promising new tool for researchers to measure the intact HIV reservoir, advancing efforts towards finding a cure for this devastating disease.

Indexed as

HIVHIV InfectionsProvirusesCD4-Positive T-LymphocytesDNA, ViralFemaleHumansNucleotidesSequence Analysis, DNAViral LoadDNA, ViralNucleotidesHIVHIV persistencethird-generation sequencing

Identifiers

PMID37843370
PMCPMC10688329
OpenAlexW4387661916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.